West Pharma (WST) Tops Q4 EPS by 5c, initiates FY 2024 guidance

West Pharma (NYSE: WST) reported Q4 EPS of $1.83, $0.05 better than the analyst estimate of $1.78. Revenue for the quarter came in at $732 million versus the consensus estimate of $739.46 million.

GUIDANCE:

West Pharma sees FY2024 EPS of $7.50-$7.75, versus the consensus of $8.78. West Pharma sees FY2024 revenue of $3-3.025 million, versus the consensus of $3.212 million.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance